ArticleThe journal of pathology. Clinical research2024

The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features.

Hélène Salaün et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.